1. Patient-reported outcomes from FLAURA: Osimertinib versus erlotinib or gefitinib in patients with EGFR-mutated advanced non-small-cell lung cancer. (January 2020) Authors: Leighl, Natasha B.; Karaseva, Nina; Nakagawa, Kazuhiko; Cho, Byoung-Chul; Gray, Jhanelle E.; Hovey, Tina; Walding, Andrew; Rydén, Anna; Novello, Silvia Journal: European journal of cancer Issue: Volume 125(2020) Page Start: 49 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Selumetinib Plus Adjuvant Radioactive Iodine in Patients With High-Risk Differentiated Thyroid Cancer: A Phase III, Randomized, Placebo-Controlled Trial (ASTRA). Issue 17 (10th June 2022) Authors: Ho, Alan L.; Dedecjus, Marek; Wirth, Lori J.; Tuttle, R. Michael; Inabnet, William B.; Tennvall, Jan; Vaisman, Fernanda; Bastholt, Lars; Gianoukakis, Andrew G.; Rodien, Patrice; Paschke, Ralf; Elisei, Rossella; Viola, David; So, Karen; Carroll, Danielle; Hovey, Tina; Thakre, Bhavana; Fagin, James A. Journal: Journal of clinical oncology Issue: Volume 40:Issue 17(2022) Page Start: 1870 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗